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The cytotoxicity of the dichloromethane crude extract (DCE), obtained from the aerial parts of Pothomorphe umbellata (L.) Miq
(Piperaceae), was evaluated against nine human cancer cell lines (MCF-7, NCI-ADR/RES, OVCAR-3, PC-3, HT-29, NCI-H460,
786-O, UACC-62, K-562). The DCE presented antiproliferative activity with good potency against all cell lines at low
concentrations (between 4.0 and 9.5 µg/mL) and with selectivity (1.55 µg/mL) for the leukemia cell line (K-652). DCE (100, 200,
300 and 400 mg/kg, ip) was also evaluated in the Ehrlich ascites tumor model. Both the survival number and the life span of the
animals that died increased by at least 45 and 50%, respectively (8 animals per group), demonstrating P. umbellata extract
potential anticancer activity. The results of the in vivo antitumor activity prompted the fractionation of the crude extract. The crude
extract was submitted to dry column chromatography with dichloromethane-methanol (99:1). The column effluent fractions were
extracted with methanol, dried under vacuum yielding fractions FR1 (less polar), FR2 (medium polarity), and FR3 (polar), which
were analyzed for their growth inhibition or cytotoxic properties by a 48-h sulforhodamine B cell viability assay by measuring the
total protein content. FR1 demonstrated high potency and cytotoxicity, a result compatible with the high toxicity of oxalic acid;
FR2, containing 4-nerolidylcathecol, presented the lowest cytotoxic activity compared to the other two fractions but with
selectivity for prostate cancer cell line; FR3, containing a mixture of steroids described in the literature as possessing various
biological activities, also presented potent anticancer in vitro activity. These results suggest that P. umbellata DCE in vivo
antitumor activity may be a consequence of the activity of different active principles.
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For many centuries, plants have provided a rich source
of therapeutic agents and bases for synthetic drugs. De-
spite the great development of organic synthesis, currently
25% of prescribed drugs worldwide are still derived from
plant sources, showing that plant species are still an im-
portant source of new drugs for diseases that continue to
lack a cure, such as cancer (1).
Pothomorphe umbellata, also known as “pariparoba”,
is a Brazilian shrub with large round leaves and inflores-
cence with small conical white and hermaphrodite flowers
(2). In folk medicine, this plant is used for the treatment of
a variety of diseases described in the first edition of the
Brazilian Pharmacopoeia (3). A great amount of pharma-
cological studies have been undertaken with this species
and, as a result, many extracts obtained from this plant
have demonstrated interesting biological actions such as
photo-protection (4), anti-inflammatory, analgesic (5), and
anti-ophidian properties (6). Many of these studies focus
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on the biological activity of 4-nerolidylcathecol, already
described by Kijjoa et al. (7). Few data mention, however,
the potential anticancer activity of this species (8,9). Thus,
we investigated the antitumor activity of dichloromethane
crude extract (DCE) and fractions obtained from P. umbel-
lata.
In order to investigate the antitumor activity, fresh
aerial parts of P. umbellata were collected at the Centro
Pluridisciplinar de Pesquisas Químicas, Biológicas e
Agrícolas experimental field (Campinas, SP, Brazil). The
plant was identified by Dr. Maria do Carmo E. Amaral
(Instituto de Biologia, UNICAMP, Campinas, SP, Brazil)
and placed in the Universidade Estadual de Campinas’
Herbarium collection, under #127.123. Fresh ground leaves
(100 g) were extracted by maceration with 1000 mL dichlo-
romethane P.A. (Merck, Germany). The solvent was evapo-
rated under reduced pressure at 30°C, providing 2.5 g, a
2.5% yield of DCE. The crude extract was submitted to dry
column chromatography with dichloromethane-methanol
(99:1). The column fractions were extracted with metha-
nol, dried under vacuum, and the resulting FR1 (less
polar), FR2 (medium polarity) and FR3 (polar) fractions
were submitted to in vitro cytotoxicity analysis. The sepa-
ration of the compound was monitored by thin layer chro-
matography (dichloromethane-methanol, 98:2) performed
on precoated plates (775554, Merck). The three fractions
were also analyzed using a gas chromatography/mass
spectrometry system (GC/MS, Hewlett-Packard, 6890/
5975, USA) equipped with a J&W Scientific DB-5 fused
silica capillary column (25 m x 0.2 mm x 0.33 µm). The
temperature of the program used was: 110°C (2 min); 5°C/
min until 300°C; injector and detector temperature: 250°C.
Helium was employed as the carrier gas. The MS were
taken at 70eV. Scanning speed was 0.84 scans/s from 40
to 550.
Since different cell lines display various sensitivities
towards cytotoxic compounds, the use of more than one
cell line was therefore considered necessary for the detec-
tion of these substances. The activity-guided fractionation
of dichloromethane soluble extract was monitored by in
vitro cytotoxic activity assay in UACC-62 (melanoma),
MCF-7 (breast), NCI-H460 (lung, non-small cells), OVCAR-
3 (ovarian), PC-3 (prostate), HT-29 (colon), 786-O (renal),
NCI-ADR/RES (ovarian expressing phenotype multiple
drugs resistance) and K-562 (leukemia) cancer cell lines.
A 48-h sulforhodamine B cell viability assay was per-
formed to determine growth inhibition and cytotoxic prop-
erties of DCE and fractions (10). Extracts and fractions
were tested on the 9 cell lines over a 3-log concentration
range (0, 0.25, 2.5, 25, and 250 µg/mL). The absorbance
data (540 nm) was the starting point for the construction of
a dose-response curve. According to Holbeck (11), three
endpoints can be calculated for each cell line. The GI50 is
the concentration required to inhibit 50% of the cell line
growth compared to the untreated ones (which corre-
sponds to 0 µg/mL point). The TGI is the concentration that
causes total growth inhibition and the LC50 is the concen-
tration needed to kill 50% of the cells (11). In the present
research, we used the TGI endpoint to compare the po-
tency and specificity of the extracts and the fractions.
Doxorubicin was used as a positive control because of its
large range of activity against many solid tumors and
leukemias.
For the in vivo studies, adult male Swiss mice were
obtained from CEMIB (UNICAMP) and maintained under
controlled conditions of temperature (22-24°C), light (12-h
light/12-h dark), and humidity (45-65%), with food and
water ad libitum. All animals used for the experimental
research had a body weight of 30-40 g. All procedures
were in accordance with the Bioethics Committee of the
Instituto de Biologia (CEEA, UNICAMP, protocol 887-1
guidelines).
Three groups of 5 animals each were treated with 100,
300 and 1000 mg/kg DCE (ip). The number of deaths was
determined during the following 15 days and afterwards all
animals were sacrificed. The LD50, showing which concen-
trations produced potential therapeutic activity but did not
kill the animals (12), was calculated by linear regression.
Ehrlich tumor cells were maintained in male Swiss
mice using serial ip inoculation at 7-day intervals in ascitis
form. After preparing the cells, the total number was deter-
mined by the trypan blue dye exclusion method, with tumor
cell viability always higher than 90%. The cells were then
diluted in 0.9% saline for final inoculation density (1 x 105
cells/mL).
P. umbellata DCE antitumor activity was evaluated in
two long-term (90 days) Ehrlich-ascites tumor (EAT) as-
says (13). Three groups of 8 animals each in the first term
and five groups of 8 animals in the second term received
105 cells/mL, ip. Drug administration (ip) began on the 4th
day after inoculation, and the groups received the follow-
ing treatments: saline (vehicle) as negative control; 5 mg/
kg doxorubicin (Tecnofarma International, St. Louis, MO,
USA) as positive control; 300 mg/kg DCE in the pilot
experiment and in 3 doses in the second experiment (100,
200 and 400 mg/kg). The animals were treated again at the
same doses on the 14th and 21st days after inoculation
and were observed and scored daily for behavior and
clinical conditions according to Ullman-Cullere and Foltz
(14). When an animal received a score of 16 or more,
according to these criteria, the animal was sacrificed and
that day was considered to be the day of its death. Kaplan-
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Meier survival curves were analyzed by the log-rank test.
The DCE in vitro cytotoxicity evaluation demonstrated
a high potency showing a good concentration and effect
relationship, with more selectivity for leukemia cell line (K-
562), with a TGI of 1.55 µg/mL. The positive control,
doxorubicin, showed high cytotoxic activity in most cell
lines with the exception for NCI-ADR/RES, which expressed
a multidrug resistance phenotype, a fact in accordance
with the TGI of 136.96 µg/mL (Table 1). This high in vitro
cytotoxicity prompted the study of DCE activity in a murine
cancer model.
Before the study in a murine cancer model, a short
acute toxicity evaluation was conducted in order to deter-
mine the LD50 and the doses to be used in long-term
studies. After treatment, the behavior and death during 15
days of DCE-treated mice were observed. With 100 and
200 mg/kg, animals demonstrated an increase in explor-
atory and locomotory activities. However, a higher dose
(1000 mg/kg) produced death. The number of deaths by
group generated a LD50 value of 533.71 mg/kg. Therefore,
this dose was used as a parameter for planning the treat-
ment of animals with EAT. The in vivo antitumor activity
was determined by the survival time and number of deaths
of the treated groups compared to the control (Figure 1). In
Figure 1A, the 300 mg/kg dose increased survival by 50%
compared to the negative control group. It also increased
the life span in almost 50%, with the first death occurring
only 50 days after the beginning of the experiment. There
was 100% survival in the doxorubicin group, demonstrat-
ing antitumoral activity (Figure 1A and B). The 400 mg/kg
Table 1. Concentration of Pothomorphe umbellata fractions re-
quired for total growth inhibition of tumor cell lines.
Cell line Total growth inhibition
DCE FR1 FR2 FR3 DOX
UACC-62 5.73 2.79 39.7 0.11 0.27
MCF-7 8.96 0.29 12.3 0.08 68.5
NCI-H460 4.28 0.12 191.3 0.24 4.68
K-562 1.55 0.04 8.57 0.05 1.39
OVCAR-3 6.08 0.90 11.8 0.03 38.1
PC-3 5.34 7.36 4.84 2.68 12.6
HT-29 9.38 5.89 32.8 0.38 112
786-O 6.55 10.3 14.6 1.73 7.69
NCI-ADR/RES 9.32 0.03 17.3 0.15 137
Data are reported as µg/mL for 3 replicates per treatment in two
independent tests at 25°C for 48 h. DCE = dichloromethane
crude extract; FR1, FR2 and FR3 = crude extract fractions; DOX
= doxorubicin (positive control).
Figure 1. Kaplan-Meier survival curves of mice (8 animals per group) treated with Pothomorphe umbellata dichloromethane crude
extract. Doses (A) 300 mg/kg (P = 0.0002) and (B) 100 (P < 0.0001), 200 (P < 0.0001), and 400 mg/kg (P < 0.0001). Controls: saline
(negative) and doxorubicin (positive, 5 mg/kg). Day 0 is the day of cell inoculation and days 4, 11 (A) and 4, 11 and 18 (B) are the days
of treatment. The survival curves were analyzed by the rank-log test, which indicates the statistical difference between the number of
deaths in the negative control group (saline) and the treated ones.
DCE dose presented high toxicity causing the whole group
to die before the negative control group (Figure 1B). Fur-
thermore, 100 and 200 mg/kg DCE doses increased the
survival rate by 50% or more.
The antitumor activity observed for this animal model
prompted the identification of the main compounds of the
fractions involved in anticancer activity. The active frac-
tions were analyzed by GC/MS. Comparison of experi-
mental data with the literature (15,16) and Nist database
available in the GC/MS demonstrated the following: the
FR1 fraction is a mixture of oxalic acid derivatives, FR2
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contains 4-nerolidylcathecol as the major component, and
the FR3 fraction is a mixture of ß-sitosterol, stigmasterol
and campesterol with m/z 414, 412 and 400, respectively.
The fact of fraction FR1 being rich in oxalic acid deriva-
tives can be correlated with the high toxicity observed in
DCE high doses. If the TGI values of DCE and FR1 are
compared (Table 1), it is remarkable that the specific
activity increased just two times for UACC-62 but 310
times for NCI-ADR/RES, while the other 5 TGI are in this
range. The highest potency of FR1 was against NCI-ADR/
RES, followed by K-562, NCI-H460 and MCF-7 TGI val-
ues. This activity against different cell lines might arise
from different mechanisms of action used by the different
chemical components of FR1 in order to kill tumor cell lines.
Fraction FR2 has 4-nerolidylcathecol as the main com-
ponent and has the lowest cytotoxicity among the three
fractions evaluated. When compared to DCE TGI values, it
is noticeable that FR2 loses its potency for all cell lines,
except for PC-3. This high selectivity for a prostate cancer
cell should be considered for further studies. The minor
cytotoxic activity cannot be definitely attributed to 4-
nerolidylcathecol because this compound was not totally
purified. However, other data attribute considerable cyto-
toxic action to this molecule (8,9). The topoisomerase I
inhibition attributed to 4-nerolidylcathecol (8) could also
corroborate the in vivo antitumor activity observed.
The polar fraction FR3 also had high potency, with a
TGI value below 0.5 µg/mL for most cell lines and in-
creased the specific activity for all cell lines (Table 1). This
fraction consists of a mixture of ß-sitosterol, stigmasterol
and campesterol steroids that had a high cytotoxicity for
OVCAR-3 and K-562 cell lines, followed by MCF-7, UACC-
62 and NCI-ADR/RES. These steroids, mainly ß-sitosterol,
have demonstrated anti-inflammatory and cytotoxic activi-
ties through steroidal receptors and membrane alteration
that induce apoptotic processes among other effects (17).
The present study is the first that shows P. umbellata
DCE cytotoxic activity, with high potency for cell growth
inhibition at low concentrations (below 10 µg/mL), and also
with in vivo activity in EAT model. In this model, P. umbellata
DCE antitumor action was confirmed by prolongation of
the life span. These results are very important, considering
that the control group died 25 days after tumor cell inocu-
lation compared to 55 days for the first death in the group
treated with 300 mg/kg. The 100 and 200 mg/kg doses also
presented a similar effect. The 100, 200 and 300 mg/kg
doses can act as a therapeutic compound with no serious
adverse reactions. Whereas with the 400 mg/kg dose,
quick death indicates that this dose is closer to the lethal
dose than to the therapeutic one. In previous studies, the
activity of diverse P. umbellata extracts in in vitro and in
vivo models demonstrated that this species can be a
potential source of new therapeutic agents for the treat-
ment of inflammatory disease (4-6). This anti-inflammatory
activity could partially explain the in vivo antitumor activity
observed with DCE since the literature has shown a good
relationship between these activities (18). DCE also pre-
sented anti-inflammatory activity when evaluated on ear
edema induced by croton oil (Sacoman JL, Foglio MA,
Carvalho JE, unpublished data).
In conclusion, the anticancer activity of the extract and
fractions from P. umbellata observed in these experimen-
tal models suggests the participation of different com-
pounds with distinct mechanisms of action. These results
are very consistent with others demonstrating the huge
potential of the Piperaceae family as a source for new drug
development (19).
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